Dr. Brian A. Jonas, M.D., PHD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of California, Davis School of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 234
Licensed in California since 2008, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: University of California, Davis School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A105278 (first issued 2008; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of California Davis Medical Center Sacramento, CA
- Enloe Health Chico, CA
- Adventist Health Sonora Sonora, CA
- Adventist Health and Rideout Marysville, CA
- Marshall Medical Center Placerville, CA
Medical groups
- Regents of the Univ of Ca (1,584 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 234
- Services billed
- 1,314
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 372 | 58 |
| Established patient office or other outpatient visit, 40-54 minutes | 257 | 133 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 187 | 39 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 96 | 68 |
| New patient office or other outpatient visit, 60-74 minutes | 66 | 66 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 22 | 20 |
| Established patient office or other outpatient visit, 30-39 minutes | 20 | 17 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 15 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 16 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Sacramento, CA | 103 |
| Venclexta (venetoclax) | 63 |
| Idhifa (enasidenib mesylate) | 40 |
| Sprycel (dasatinib) | 37 |
| Iclusig (ponatinib hcl) | 36 |
| Levofloxacin Other prescribers in Sacramento, CA | 31 |
| Imatinib Mesylate | 28 |
| Cresemba (isavuconazonium sulfate) | 25 |
| Ondansetron Hcl Other prescribers in Sacramento, CA | 24 |
| Allopurinol Other prescribers in Sacramento, CA | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 8 payments worth $9,554 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $2,865 |
|---|---|
| Daiichi Sankyo Inc. | $2,580 |
| AbbVie Inc. | $2,363 |
| Genentech USA, Inc. | $1,537 |
| Secura Bio, Inc. | $184 |
| Rigel Pharmaceuticals, Inc. | $25.54 |
| Consulting Fee | $9,138 |
|---|---|
| Food and Beverage | $417 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Aug 14, 2025 | Consulting Fee | $2,865 |
| Daiichi Sankyo Inc. Feb 19, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $2,580 |
| AbbVie Inc. Jan 24, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,688 |
| Genentech USA, Inc. Dec 6, 2025 | Consulting Fee Venclexta · BioOncology | $1,330 |
| AbbVie Inc. Mar 18, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $675 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $32,408 in research payments for these studies, mostly to the institutions running them.
- Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
AbbVie Inc. · Completed · NCT02997761 - A20-266 - Phase 2 study of venetoclax with alternative HMA for patients with treatment unfit AML with prior HMA failure
AbbVie Inc. - Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT06068868
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.